Cargando…

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

Detalles Bibliográficos
Autores principales:	Corre, Jill, Montes, Lydia, Martin, Elodie, Perrot, Aurore, Caillot, Denis, Leleu, Xavier, Belhadj, Karim, Facon, Thierry, Hulin, Cyrille, Mohty, Mohamad, Fontan, Jean, Macro, Margaret, Brechignac, Sabine, Jaccard, Arnaud, Stoppa, Anne-Marie, Orsini-Piocelle, Frederique, Adiko, Didier, Voillat, Laurent, Keddar, Faiza, Barry, Marly, Demarquette, Helene, Certain, Marie-Noelle, Plantier, Isabelle, Roussel, Murielle, Hébraud, Benjamin, Filleron, Thomas, Attal, Michel, Avet-Loiseau, Hervé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556617/ https://www.ncbi.nlm.nih.gov/pubmed/33054068 http://dx.doi.org/10.3324/haematol.2019.236588

Ejemplares similares

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
por: Schavgoulidze, A., et al.
Publicado: (2022)

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
por: Schavgoulidze, Anaïs, et al.
Publicado: (2023)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
por: Bobin, A., et al.
Publicado: (2022)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
por: Macro, M., et al.
Publicado: (2022)

Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells
por: Espagnolle, Nicolas, et al.
Publicado: (2020)

P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).
por: Macro, Margaret, et al.
Publicado: (2023)

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
por: Fouquet, Guillemette, et al.
Publicado: (2018)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2022)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
por: Hulin, C., et al.
Publicado: (2022)

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma
por: Lemaitre, Léa, et al.
Publicado: (2020)

Logic programming reveals alteration of key transcription factors in multiple myeloma
por: Miannay, Bertrand, et al.
Publicado: (2017)

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
por: Bradwell, A, et al.
Publicado: (2013)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
por: Michallet, M, et al.
Publicado: (2018)

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
por: Facon, Thierry, et al.
Publicado: (2019)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
por: Kendrick, Felicity, et al.
Publicado: (2017)

Expressed fusion gene landscape and its impact in multiple myeloma
por: Cleynen, A., et al.
Publicado: (2017)

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
por: Facon, Thierry, et al.
Publicado: (2022)

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
por: Macro, M., et al.
Publicado: (2022)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma
por: Alberge, Jean-Baptiste, et al.
Publicado: (2020)

Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization
por: Pertesi, Maroulio, et al.
Publicado: (2015)

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

Memory loss during lenalidomide treatment: a report on two cases
por: Rollin-Sillaire, Adeline, et al.
Publicado: (2013)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Deciphering the chronology of copy number alterations in Multiple Myeloma
por: Aktas Samur, Anil, et al.
Publicado: (2019)

B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK
por: Roussel, M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3jrv508egttc885pu5ddrerokh